If the sNDA is accepted and Sulfari is granted priority review, this critically important medication could become available to patients by the end of this year, marking what could be the first FDA approved treatment in FSGS. Travir has guided that the commercial opportunity in FSGS is at least as large as an IgAN and approval would mark an important accomplishment in our commercial portfolio. In terms of additional pipeline updates, Agenus (NASDAQ: AGEN ) presented compelling data in several colorectal cancer treatment settings at the recent ASCO GI conference. Their efforts to secure a development and commercial partner remain ongoing. Palbella recently initiated clinical studies of cutorin rapamycin in two serious rare dermatological conditions.